Argenx stock gains momentum after Forte Biosciences acquisition closes

Published on 09/13/2026 at 14:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx stock is backed by a completed cash tender offer for Forte Biosciences at USD 77.00 per share as of August 27, 2026, strengthening its immunology pipeline. As of September 11, 2026, the company’s market capitalization stands at about USD 61.21 billion, reflecting solid long-term growth.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

Argenx stock (ISIN NL0010832176) is trading with solid backing from a recently completed acquisition of Forte Biosciences valued at USD 77.00 per share, a deal that closed on August 27, 2026 and expanded Argenx’s immunology pipeline.

Forte Biosciences acquisition underpins growth

According to StockTitan, Argenx BV completed a cash tender offer for Forte Biosciences at USD 77.00 per share, with approximately 87.13 percent of Forte’s outstanding shares validly tendered and irrevocably accepted for payment as of one minute after 11:59 p.m. Eastern Time on August 26, 2026.

As the same filing notes, the merger was consummated on August 27, 2026 under Section 251(h) of the Delaware General Corporation Law, turning Forte Biosciences into a wholly owned subsidiary of Argenx and effectively removing Forte from Nasdaq listing and Exchange Act reporting obligations through planned Forms 25 and 15.StockTitan

Deal economics and operating context

The USD 77.00 per share cash consideration for Forte represents the key economic figure for the transaction and sets the baseline for how much Argenx is investing to bring Forte’s dermatology and immunology assets into its portfolio.StockTitan In connection with the merger, Forte director Stephen K. Doberstein’s Form 4 filing shows multiple option grants with exercise prices below USD 77.00 being cancelled and converted into lump-sum cash payments, illustrating the premium embedded in the offer price compared with earlier grant levels ranging from USD 7.54 to USD 31.75 per share.StockTitan

From an investor perspective, this acquisition adds clinical-stage assets and know-how to Argenx’s existing immunology and antibody platforms, reinforcing the growth narrative that has already driven a substantial increase in the company’s market capitalization over recent years. As of September 2026, Argenx’s market cap stands at about USD 61.21 billion, up around 16.34 percent compared with the level reported for 2025, signalling continued long-term value creation.CompaniesMarketCap On September 11, 2026, Nasdaq data cited by CompaniesMarketCap shows Argenx’s market cap at USD 61.09 billion, very close to the USD 61.21 billion figure reported by the portal, underlining the stability of its valuation at this level.CompaniesMarketCap

Stock level and investor takeaways

While recent search results focus on market capitalization rather than an exact same-day quote, the roughly USD 61.21 billion market cap as of September 11, 2026 positions Argenx among the world’s 412th most valuable listed companies, giving investors a sense of its scale compared with global peers.CompaniesMarketCap For retail investors, the combination of a completed cash acquisition at a defined USD 77.00 per share price and double-digit percentage growth in market cap over the 2025 to 2026 period offers a concrete basis to assess how Argenx is deploying capital to expand its immunology franchise.